NKTR Nektar Therapeutics

NASDAQ
$57.06

Nektar Therapeutics (NKTR) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $2.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.9% since its last earnings release on August 13, 2026.

Nektar Therapeutics Beat Consensus Estimates
Thursday, August 13, 2026 · 4:15 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:15 PM ET
Earnings Whisper
-
vs ($2.20)
Rev est $10.22M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $68.77

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Nektar Therapeutics

Nektar Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops a pipeline of drug candidates that utilizes its PEGylation and polymer conjugate technology platforms that are designed to develop molecular entities.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.